News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,813 Results
Type
Article (39537)
Company Profile (247)
Press Release (656029)
Section
Business (204096)
Career Advice (2007)
Deals (35412)
Drug Delivery (94)
Drug Development (81005)
Employer Resources (172)
FDA (16150)
Job Trends (14843)
News (345030)
Policy (32495)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2546)
Accelerated approval (2)
Adcomms (20)
Allergies (80)
Alliances (49363)
ALS (81)
Alzheimer's disease (1345)
Antibody-drug conjugate (ADC) (107)
Approvals (16153)
Artificial intelligence (226)
Autoimmune disease (13)
Automation (14)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (175)
Bladder cancer (56)
Brain cancer (24)
Breast cancer (245)
Cancer (1965)
Cardiovascular disease (153)
Career advice (1673)
Career pathing (29)
CAR-T (139)
Cell therapy (393)
Cervical cancer (17)
Clinical research (65662)
Collaboration (760)
Compensation (446)
Complete response letters (19)
COVID-19 (2580)
CRISPR (34)
C-suite (203)
Cystic fibrosis (98)
Data (1919)
Decentralized trials (2)
Denatured (16)
Depression (36)
Diabetes (246)
Diagnostics (6329)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (110)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (84)
Earnings (86139)
Editorial (31)
Employer branding (21)
Employer resources (146)
Events (111579)
Executive appointments (627)
FDA (17243)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (682)
Gene editing (94)
Generative AI (18)
Gene therapy (272)
GLP-1 (679)
Government (4377)
Grass and pollen (4)
Guidances (48)
Healthcare (18802)
Huntington's disease (22)
IgA nephropathy (21)
Immunology and inflammation (102)
Indications (26)
Infectious disease (2708)
Inflammatory bowel disease (131)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (83)
Interviews (311)
IPO (16484)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (34)
Layoffs (448)
Leadership (15)
Legal (7899)
Liver cancer (70)
Lung cancer (288)
Lymphoma (129)
Machine learning (2)
Management (58)
Manufacturing (265)
MASH (60)
Medical device (13313)
Medtech (13318)
Mergers & acquisitions (19393)
Metabolic disorders (627)
Multiple sclerosis (68)
NASH (16)
Neurodegenerative disease (75)
Neuropsychiatric disorders (24)
Neuroscience (1807)
NextGen: Class of 2025 (6513)
Non-profit (4476)
Northern California (2392)
Now hiring (37)
Obesity (339)
Opinion (201)
Ovarian cancer (71)
Pain (75)
Pancreatic cancer (76)
Parkinson's disease (130)
Partnered (20)
Patents (200)
Patient recruitment (93)
Peanut (46)
People (57052)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20448)
Phase II (28917)
Phase III (21550)
Pipeline (973)
Podcasts (44)
Policy (107)
Postmarket research (2563)
Preclinical (8648)
Press Release (64)
Prostate cancer (92)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (352)
Real estate (5900)
Recruiting (65)
Regulatory (22119)
Reports (46)
Research institute (2316)
Resumes & cover letters (349)
Rett syndrome (3)
RNA editing (3)
RSV (37)
Schizophrenia (62)
Series A (120)
Series B (77)
Service/supplier (11)
Sickle cell disease (49)
Southern California (2065)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (12)
Supply chain (59)
The Weekly (25)
United States (20886)
Vaccines (653)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Today (82)
Last 7 days (605)
Last 30 days (2483)
Last 365 days (33550)
2025 (7706)
2024 (35222)
2023 (40077)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (717)
Alabama (49)
Alaska (7)
Arizona (223)
Arkansas (13)
Asia (37693)
Australia (6161)
California (5451)
Canada (1857)
China (468)
Colorado (244)
Connecticut (256)
Delaware (123)
Europe (80805)
Florida (809)
Georgia (190)
Idaho (57)
Illinois (489)
India (23)
Indiana (289)
Iowa (9)
Japan (141)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (824)
Massachusetts (4098)
Michigan (208)
Minnesota (366)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1551)
New Mexico (28)
New York (1563)
North Carolina (911)
North Dakota (7)
Northern California (2392)
Ohio (190)
Oklahoma (14)
Oregon (33)
Pennsylvania (1244)
Puerto Rico (9)
Rhode Island (26)
South America (1094)
South Carolina (18)
South Dakota (1)
Southern California (2065)
Tennessee (92)
Texas (812)
Utah (163)
Virginia (127)
Washington D.C. (57)
Washington State (507)
West Virginia (3)
Wisconsin (49)
695,813 Results for "rayzebio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).
February 26, 2024
·
5 min read
Deals
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion.
February 12, 2024
·
6 min read
Biotech Bay
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
Bristol Myers Squibb announced that its previously announced tender offer to acquire all of the outstanding shares of RayzeBio, Inc. common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024.
February 23, 2024
·
5 min read
Deals
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Bristol Myers Squibb and RayzeBio, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
December 26, 2023
·
15 min read
Deals
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing of its upsized $311 million initial public offering of 17,277,600 shares of common stock at a price to the public of $18.00 per share.
September 14, 2023
·
3 min read
Biotech Beach
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023.
November 6, 2023
·
1 min read
Deals
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
RayzeBio, Inc. (Nasdaq: RYZB) today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share.
September 19, 2023
·
3 min read
Business
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced the appointment of Tim Van Hauwermeiren to its board of directors.
November 1, 2023
·
4 min read
Business
RayzeBio Appoints Christy Oliger to its Board of Directors
RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors.
August 29, 2023
·
2 min read
Business
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.
November 13, 2023
·
8 min read
1 of 69,582
Next